6-methylenandrosta-1,4-diene-3,17-dione CAS NO.107868-30-4

Min.Order Quantity:: 1 Metric Ton

Purity:: 98.00%

Port:: Shanghai

Payment Terms:: L/C,D/A,D/P,T/T,MoneyGram

Add to Inquiry Cart

Product Details

Keywords

Exemestane
107868-30-4
C20H24O2

Quick Details

ProName: 6-methylenandrosta-1,4-diene-3,17-dion...
CasNo: 107868-30-4
Molecular Formula: C20H24O2
Appearance: white to light yellow crystal powder
Application: Organic Chemistry
DeliveryTime: Prompt
PackAge: As buy's request
Port: Shanghai
ProductionCapacity: 10 Metric Ton/Day
Purity: 98.00%
Storage: Room Temperature
Transportation: as per msds
LimitNum: 1 Metric Ton
Grade: Industrial Grade,Food Grade,Pharma Gra...

Superiority

high quality,high purity

exemestane basic information

introduction function and use synthesis indications usage and dosage adverse reactions contraindications clinical assessment attentions drug interactions specification chemical properties applications producing method

product name:	exemestane
synonyms:	6-methylenandrosta-1,4-diene-3,17-dione;6-methyleneandrosta-1,4-diene-3,17-dione;10,13-dimethyl-6-methylidene-7,8,9,10,11,12,13,14,15,16-decahydrocyclopenta[a]phenanthrene-;exemestane;fce-24304;aromasin;exemestan;exemestance
cas:	107868-30-4
mf:	c20h24o2
mw:	296.4
einecs:
product categories:	active pharmaceutical ingredients;chiral;antineoplastic (hormonal);intermediates & fine chemicals;pharmaceuticals;steroids;pfizer compounds;steroid and hormone;api;anti-cancer&immunity;inhibitors
mol file:	107868-30-4.mol

Details

exemestane chemical properties

mp	155.13°c
storage temp.	store at -20°c
cas database reference	107868-30-4(cas database reference)

safety information

hazard codes	t,n
risk statements	60-61-51
safety statements	53-22-36/37-57
hazardous substances data	107868-30-4(hazardous substances data)

msds information

provider	language
10,13-dimethyl-6-methylidene-7,8,9,10,11,12,13,14,15,16-decahydrocyclopenta[a]phenanthrene-	english

exemestane usage and synthesis

introduction	exemestane is a kind of irreversible nonsteroidal aromatase inhibitors, whose structure is similar to its substrate the natural androstenedione. it’s an effective and optional approach to treat postmenopausal women steroid-dependent breast cancer by inhibiting the aromatase to deprive estrogen. it’s used for advanced breast cancer of naturally or artificially postmenopausal women who have been treated with tamoxifen while the illness has yet to progress.
function and use	exemestane, steroidal aromatase inactivator, whose structure is similar with natural substrate the androstenedione of aromatase, is the pseudosubstrate of aromatase. as postmenopausal women’s estrogen is mainly transferred under the effected by aromatase in peripheral tissues with androgen (produced in adrenal cortex), this product makes the aromatase inactive through combining the irreversible active site of aromatase, and hence to significantly reduce postmenopausal estrogen level in blood circulation. this product had no obvious effect on adrenal cortical hormone biosynthesis, even if the concentration is higher than 600 times the effect of aromatase inhibition concentration, it has also no obvious effect on other enzymes in cortical hormone production. oral absorption of this product is rapid, and the oral bioavailability is 42%, which is influenced by the food. in postmenopausal women, the absorption rate of the drug is higher than that of the healthy subjects, and the peak concentration of blood drug is 2 ~ 4 hours after oral administration. the peak time is 1.2 hours, and is shorter than that of healthy subjects (2.9 hours). the binding rate of total protein is 90%, which is mainly related to the α-acid glycoprotein and protein. mainly through the liver metabolism, and the metabolite is inactive 17 - hydrogen exemestane, and elimination half-time is 24h. primarily excreted by urine or feces, each accounting for 42% of the amount of dosis. the above information is edited by the chemicalbook he liao pu.
synthesis	take androst-4-ene-3 and 17-dione (2) as raw material, firstly condense triethyl orthoformate, n-methylaniline and 40% formaldehyde solution to get 6-methylene androst-4-ene-3 and 17-dione (3), and then make dioxidation of 2,3-dichloro-5,6-ddq to get 1. in the oxidative dehydrogenation reaction, the addition of a certain amount of weak acid can shorten the reaction time from 15h to 8h, and the yield can be increased from 47% to 62%. this method has mild reaction conditions, simple separation with total yield of 45%. the synthetic route is as follows:
indications	suitable for estrogen and progesterone receptor positive postmenopausal women with advanced breast cancer.
usage and dosage	25mg for 1 time per day, oral admiration after meals. for patients with mild hepatic and renal insufficiency, it is not required to adjust the dosage of the drug.
adverse reactions	the main adverse reactions of this product are nausea, dry mouth, constipation, diarrhea, dizziness, insomnia, skin rash, fatigue, fever, edema, increased pain, vomiting, abdominal pain, increased appetite, weight gain, etc. furthermore it’s reported to cause high blood pressure, depression, anxiety, dyspnea, cough, etc. also there is decrease of lymphocyte count and liver function (such as alanine aminotransferase) abnormality.
contraindications	1. forbidden for patients allergic to this drug. 2. forbidden for pregnant, lactation women, and kids.
clinical assessment	exemestane is an oral potent irreversible steroidal aromatase inhibitor. patients on tamoxifen resistant, exemestane 25mg, qd, can get 15% to 28% of objective efficiency and 69 to 76 weeks of continuous time. exemestane is better than megestrol acetate, which can prolong the time of disease progression. for the deterioration of patient after megestrol acetate therapy, exemestane still can reach 11% ~ 13% objective efficiency. exemestane 25 mg/d, for non-steroidal aromatase inhibitor treatment failure patients, the objective response rate is 6.6%; there is no cross resistance between those two drugs.
attentions	1.premenopausal women generally do not use exemestane tablets. 2.patients in severe liver and renal function insufficiency need to use it with caution. excessive use of exemestane can lead to increased non-fatal adverse reaction. 3.pregnancy safety grade of this drug in fda is d grade. 4.no special attention for the elderly to use this drug.
drug interactions	1.this product can’t be combined with estrogen drugs, so as to avoid the effect of this product. 2.exemestane mainly metabolized by cyp3a4, but when it’s in combination with potent cyp3a4 inhibitor (ketoconazole), pharmacokinetics of the product doesn’t change, therefore it seems that cyp isoenzyme inhibitors doesn’t have significant effect on pharmacokinetics of this product, but it does not rule out the possibility that the known cyp3a4 inducers decreases exemestane concentration in plasma.
specification	tablet: 25mg. capsule: 25mg.
chemical properties	white solid, melting point 190 ~ 192℃.
applications	1.the second generation aromatase inhibitors, used for the treatment of metastatic breast cancer and used as adjuvant therapy for early breast cancer. 2.pharmaceutical raw materials, is a kind of irreversible steroid body aromatase extinguishing agent, can inhibit the synthesis of estrogen, and reduce circulating estrogen levels, applicable to the progression of disease after treatment with tamoxifen in postmenopausal patients with advanced breast cancer.
producing method	androst-4-ene-3, 17-dione (2) and triethyl orthoformate dissolved in tetrahydrofuran and anhydrous ethanol, reacting under the presence of p-toluenesulfonic acid, and then add into n-methyl aniline and formaldehyde solution to continue the reaction. the obtained mannich reaction product dissolved in anhydrous benzoic acid and anhydrous two alkyl, under the action of ddq, to get exemestane, and the total yield is 45%.
chemical properties	white to light yellow crystal powder
usage	an antineoplastic (hormonal)
usage	antiinfective
usage	labeled exemestane, intended for use as an internal standard for the quantification of exemestane by gc- or lc-mass spectrometry.